Eltanexor treatment in a patient-derived DEK-NUP214 AML xenograft model disrupted leukemia development with molecular clearance of the bone marrow after a median of 377 days, whereas control mice succumbed after a median of 244 days. The gene discussed is NUP214; the disease is acute myeloid leukemia.